Release of neuropeptide Y and hemodynamic changes during surgical removal of human pheochromocytomas

Regulatory Peptides

Volumn 86, Issue 1-3, 2000, Pages 95-102

  Eurin, Joélle ^a   Barthélemy, Christiane ^a   Masson, Françoise ^a   Maistre, Geneviève ^a   Soualmia, Hayet ^a   Noé, Eric ^a   Sarfati, Emile ^b   Eurin, Benoît ^b   Carayon, Alain ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Norepineprhine; Systemic vascular resistances

Indexed keywords

NEUROPEPTIDE Y; NORADRENALIN;

ADULT; ARTICLE; BLOOD LEVEL; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HEMODYNAMICS; HUMAN; HYPERTENSION; IMMUNOREACTIVITY; MALE; NEUROTRANSMITTER RELEASE; NORADRENALIN BLOOD LEVEL; PHEOCHROMOCYTOMA; PLASMA; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

ADRENAL GLAND NEOPLASMS; ADULT; ANALYSIS OF VARIANCE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEUROPEPTIDE Y; NOREPINEPHRINE; PHEOCHROMOCYTOMA; VASCULAR RESISTANCE;

EID: 19244378617     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(99)00092-0     Document Type: Article

References (37)

1. Adrian T.E., Allen J.M., Terenghi G., Bacarese-Hamilton A.J., Brown M.J., Polak J.M., Bloom S.R. Neuropeptide Y in pheochromocytomas and ganglioneuroblastomas. Lancet. 2:1983;540-542.
2. Allen J.M., Yeats J.C., Causon R., Brown M.J., Bloom S.R. Neuropeptide Y and its flanking peptide in human endocrine tumors and plasma. J Clin Endocrinol Metab. 64:1987;1199-1204.
3. Emson P.C., Corder R., Lowry P.J. Demonstration of a neuropeptide Y-like immunoreactivity in human phaechromocytoma extracts. Regul Pept. 8:1984;89-94.
4. Higuchi H., Iwasa A., Yokokawa K. High levels of expression of neuropeptide Y mRNA in human phaeochromocytomas. Clin Exp Pharmacol Physiol. 21:1994;359-365.
5. Senanayake P. de S., Denker J., Bravo E.L., Graham R.M. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest. 96:1995;2503-2509.
6. Corder R., Shapiro B., Lowry P.J., Bouloux P., Besser M.G., Connel J.M.C., Semple P.F., Nieuwenhuijzen-Kruseman A.C., Muller A.F., Gaillard R.C. Relationship between tumor and plasma concentrations of neuropeptide Y in patients with adrenal medullary phaeochromocytoma. J Hypertens. 4:1986;S193-S195.
7. Lundberg J.M., Hokfelt T., Hemsen A., Theodorsson-Norheim E., Pernow J., Hamberger B., Goldstein M. Neuropeptide Y-like immunoreactivity in adrenaline cells of adrenal medulla and in tumors and plasma of pheochromocytoma patients. Regul Pept. 13:1986;169-182.
8. Connell J.M.C., Corder R., Asbury I., Macpherson S., Inglis G.C., Lowry P., Burt A.D., Semple P.F. Neuropeptide Y in multiple endocrine neoplasia: Release during surgery for phaechromocytoma. Clin Endocrinol. 26:1987;75-84.
9. Januszewicz W., Wocial B., Ignatowska-Switalska H., Dutkiewicz-Raczkowska M., Feltynowski T., Januszewicz A., Tapinski M., Zukowska-Grojec Z., Szostek M. Alterations in plasma neuropeptide Y immunoreactivity and catecholamine levels during surgical removal of pheochromocytoma. J Hypertens. 16:1998;543-547.
10. Zukowska-Grojec Z., Haass M., Bayorh A. Neuropeptide Y and peptide YY mediate nonadrenergic vasoconstriction and modulate sympathetic responses in rats. Regul Pept. 15:1986;99-110.
11. Hashim M.A., Harrington W.W., Daniels A.J., Tadepalli N. Hemodynamic profile of neuropeptide Y in dogs: effects of ganglionic blockade. Peptides. 18:1997;235-239.
12. Dahlof C., Dahlof P., Lundberg J.M. Neuropeptide Y (NPY): Enhancement of blood pressure increase upon a-adrenoceptor activation and direct pressor effects in pithed rats. Eur J Pharmacol. 109:1985;289-292.
13. McDermott B.J., Millar B.C., Piper H.M. Cardiovascular effects of neuropeptide Y: receptor interactions and cellular mechanisms. Cardiovasc Res. 27:1993;893-905.
14. Waeber B., Burnier M., Nussberger J., Brunner H.R. Role of atrial natriuretic peptides and neuropeptide Y in blood pressure regulation. Horm Res. 34:1990;161-165.
15. Takahashi K., Mouri T., Sone M., Murakami O., Itoi K., Ohneda M., Yoshinaga K. Release of neuropeptide Y from pheochromocytomas. Endocrinol Japon. 37:1990;53-60.
16. Deray G., Maistre G., Cacoub P., Carayon A., Leger P., Rottembourg J., Anouar M., Sassano P., Cabrol C. Plasma concentrations of atrial natriuretic peptide in patients with artiticial and transplanted hearts. Eur J Clin Pharmacol. 34:1988;91-93.
17. Zongazo M.A., Carayon A., Masson F., Maistre G., Noé E., Eurin J., Barthelemy C., Komajda M., Legrand J.C. Effect of arginine vasopressin and extracellular osmolarity on atrial natriuretic peptide release by superfused rat atria. Eur J Pharmacol. 209:1991;45-55.
18. O'Hare M.M.T., Schwartz T.W. Expression and precursor processing of neuropeptide Y in human pheochromocytoma and neuroblastoma tumors. Cancer Res. 49:1989;7010-7014.
19. Pruszczyk P., Wocial B., Ignatowska-Switalska H., Feltynowski T., Ellafi M., Januszewicz A., Lapinski M., Zukowska-Grojec Z., Januszewicz W. Clin Chim Acta. 243:1995;205-212.
20. Plouin P.F., Chatellier G., Grouzmann E., Azizi M., Denolle T., Comoy E., Corvol P. Plasma neuropeptide Y and catecholamine concentrations and urinary metanephrine excretion in patients with adrenal or ectopic phaeochromocytoma. J Hypertens. 9:(suppl 6):1991;S272-S273.
21. Grouzmann E., Gicquel C., Plouin P.F., Schlumberger M., Comoy E., Bohuon C. Neuropeptide Y and neuron-specific enolase levels in benign and malignant pheochromocytomas. Cancer. 66:1990;1833-1835.
22. Helman U., Cohen P.S., Averbuch Sd., Cooper M.J., Keiser H.R., Israel M.A. Neuropeptide Y expression distinguishes malignant from being pheochromocytoma. J Clin Oncol. 7:1989;1720-1725.
23. Schlumberger M., Gicquel C., Lumbroso I., Tenenbaum F., Comoy E., Bosq I., Fonseca E., Ghillani P.P., Aubert B., Travagli I.P., Gardet P., Parmentier C. Malignant pheochromocytoma: clinical, biological, historic and therapeutic data in series of 20 patients with distant metastases. J Endocrinol Invest. 15:1992;631-642.
24. Tabarin A., Cassiede P., Minot A., Cuber J.C., Roger P., Ducassou D. Heterogeneity of neuropeptide Y immunoreactivity in patients with pheochromocytoma: influence on the diagnostic power of measuring plasma NPY using antisera with different specificities. Acta Endocrinol. 128:1993;243-250.
25. Maisel A.S., Scott N.A., Motulsky H.J., Michel M.C., Boublik J.H., Rivier J.E., Allen R.S., Browm M.R. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med. 86:1989;43-48.
26. Morris M.J., Russell A.E., Kapoor V., Cain M.D., Elliot J.M., West M.J., Wing L.M.H., Chalmers I.P. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst. 17:1986;143-149.
27. Hulting I., Sollevi A., Ullman B. Franco-Cereceda, Lundberg J.M. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res. 24:1990;102-108.
28. Ullman B., Franco-Cereceda A., Hulting I., Lundberg I.M., Sollevi A. Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J Intern Med. 228:1990;583-589.
29. Derchi G., Dupuis I., de Champlain I., Rouleau J.L. Paradoxical decrease in circulating neuropeptide Y-like immunoreactivity during mild orthostatic stress in subjects with and without congestive heart failure. Eur Heart J. 14:1993;34-39.
30. Pernow I., Lundberg I.M., Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci. 40:1987;47-54.
31. Hauser G.J., Danchak M.R., Colvin M.P., Hopkins R.A., Wocial B., Myers A.K., Zukowska-Grojec Z. Circulating neuropeptide Y in humans: relation to changes in catecholamine levels and changes in hemodynamics. Neuropeptides. 30:1996;159-165.
32. Dubois-Randé J.L., Comoy E., Merlet P., Benvenuti C., Carville C., Hittinger L., Macquin M., Buhuon C., Castaigne A. Relationship among neuropeptide Y catecholamines and haemodynamics in congestive heart failure. Eur Heart J. 13:1992;1233-1238.
33. Arnalich F., Sanchez J.F., Martinez M., Jimenez M., Lopez I., Vazquez I.I., Hermanz A. Changes in plasma concentrations of vasoactive neuropeptides in patients with septis and septic shock. Life Sci. 56:1995;75-81.
34. Omland T., Opstad P.K., Dickstein K. Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction. Am Heart J. 127:1994;774-779.
35. Lundberg J.M. Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acides and nitric oxides. Pharmacol Rev. 48:1996;113-178.
36. Corder R., Lowry P.J., Emson P.C., Gaillard R.C. Chromatographic characterisation of the circulating neuropeptide Y immunoreactivity from patients with phaechromocytoma. Regul Pept. 10:1985;91-97.
37. Grouzmann E., Werfeli-George P., Fathi M., Burnier M., Waeber B., Waeber G. Angiotensin-II mediates norepinephrine and neuropeptide Y secretion in a human pheochromocytoma. J Clin Endocrinol Metab. 79:1994;1852-1856.